Complementary α-arrestin-ubiquitin ligase complexes control nutrient transporter endocytosis in response to amino acids

  1. Vasyl Ivashov
  2. Johannes Zimmer
  3. Sinead Schwabl
  4. Jennifer Kahlhofer
  5. Sabine Weys
  6. Ronald Gstir
  7. Thomas Jakschitz
  8. Leopold Kremser
  9. Günther K Bonn
  10. Herbert Lindner
  11. Lukas A Huber
  12. Sebastien Leon
  13. Oliver Schmidt  Is a corresponding author
  14. David Teis
  1. Medical University of Innsbruck, Austria
  2. ADSI - Austrian Drug Screening Institute GmbH, Austria
  3. Université Paris-Diderot, France

Abstract

How cells adjust nutrient transport across their membranes is incompletely understood. Previously, we have shown that S. cerevisiae broadly re-configures the nutrient transporters at the plasma membrane in response to amino acid availability, through endocytosis of sugar- and amino acid transporters (AATs) (Müller et al., 2015). A genome-wide screen now revealed that the selective endocytosis of four AATs during starvation required the α-arrestin family protein Art2/Ecm21, an adaptor for the ubiquitin ligase Rsp5, and its induction through the general amino acid control pathway. Art2 uses a basic patch to recognize C-terminal acidic sorting motifs in AATs and thereby instructs Rsp5 to ubiquitinate proximal lysine residues. When amino acids are in excess, Rsp5 instead uses TORC1-activated Art1 to detect N-terminal acidic sorting motifs within the same AATs, which initiates exclusive substrate-induced endocytosis. Thus, amino acid excess or starvation activate complementary α-arrestin-Rsp5-complexes to control selective endocytosis and adapt nutrient acquisition.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Vasyl Ivashov

    Institute for Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  2. Johannes Zimmer

    Institute for Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  3. Sinead Schwabl

    Institute for Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  4. Jennifer Kahlhofer

    Institute for Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  5. Sabine Weys

    Division of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  6. Ronald Gstir

    ADSI - Austrian Drug Screening Institute GmbH, ADSI - Austrian Drug Screening Institute GmbH, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  7. Thomas Jakschitz

    ADSI - Austrian Drug Screening Institute GmbH, ADSI - Austrian Drug Screening Institute GmbH, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  8. Leopold Kremser

    Division of Clinical Biochemistry, ProteinMicroAnalysis Facility, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  9. Günther K Bonn

    ADSI - Austrian Drug Screening Institute GmbH, ADSI - Austrian Drug Screening Institute GmbH, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  10. Herbert Lindner

    Division of Clinical Biochemistry, ProteinMicroAnalysis Facility, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  11. Lukas A Huber

    Institute for Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  12. Sebastien Leon

    Institut Jacques Monod, Université Paris-Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2536-8595
  13. Oliver Schmidt

    Institute for Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    For correspondence
    oliver.schmidt@i-med.ac.at
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7921-4663
  14. David Teis

    Division of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8181-0253

Funding

European Molecular Biology Organization (ALTF 642-2012)

  • Oliver Schmidt

European Molecular Biology Organization (EMBOCOFUND2010)

  • Oliver Schmidt

European Molecular Biology Organization (GA-2010-267146)

  • Oliver Schmidt

Tiroler Wissenschaftsfond (2015)

  • Oliver Schmidt

Austrian Science Fund (FWF-Y444-B12)

  • David Teis

Austrian Science Fund (P30263)

  • David Teis

Austrian Science Fund (P29583)

  • David Teis

Agence Nationale de la Recherche (ANR-16-CE13-0002-01)

  • Sebastien Leon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Ivashov et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,428
    views
  • 378
    downloads
  • 30
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Vasyl Ivashov
  2. Johannes Zimmer
  3. Sinead Schwabl
  4. Jennifer Kahlhofer
  5. Sabine Weys
  6. Ronald Gstir
  7. Thomas Jakschitz
  8. Leopold Kremser
  9. Günther K Bonn
  10. Herbert Lindner
  11. Lukas A Huber
  12. Sebastien Leon
  13. Oliver Schmidt
  14. David Teis
(2020)
Complementary α-arrestin-ubiquitin ligase complexes control nutrient transporter endocytosis in response to amino acids
eLife 9:e58246.
https://doi.org/10.7554/eLife.58246

Share this article

https://doi.org/10.7554/eLife.58246

Further reading

    1. Cell Biology
    Yajun Zhai, Peiyi Liu ... Gongzheng Hu
    Research Article

    Discovering new strategies to combat the multidrug-resistant bacteria constitutes a major medical challenge of our time. Previously, artesunate (AS) has been reported to exert antibacterial enhancement activity in combination with β-lactam antibiotics via inhibition of the efflux pump AcrB. However, combination of AS and colistin (COL) revealed a weak synergistic effect against a limited number of strains, and few studies have further explored its possible mechanism of synergistic action. In this article, we found that AS and EDTA could strikingly enhance the antibacterial effects of COL against mcr-1- and mcr-1+ Salmonella strains either in vitro or in vivo, when used in triple combination. The excellent bacteriostatic effect was primarily related to the increased cell membrane damage, accumulation of toxic compounds and inhibition of MCR-1. The potential binding sites of AS to MCR-1 (THR283, SER284, and TYR287) were critical for its inhibition of MCR-1 activity. Additionally, we also demonstrated that the CheA of chemosensory system and virulence-related protein SpvD were critical for the bacteriostatic synergistic effects of the triple combination. Selectively targeting CheA, SpvD, or MCR using the natural compound AS could be further investigated as an attractive strategy for the treatment of Salmonella infection. Collectively, our work opens new avenues toward the potentiation of COL and reveals an alternative drug combination strategy to overcome COL-resistant bacterial infections.

    1. Cell Biology
    2. Genetics and Genomics
    Adam D Longhurst, Kyle Wang ... David P Toczyski
    Tools and Resources

    Progression through the G1 phase of the cell cycle is the most highly regulated step in cellular division. We employed a chemogenetic approach to discover novel cellular networks that regulate cell cycle progression. This approach uncovered functional clusters of genes that altered sensitivity of cells to inhibitors of the G1/S transition. Mutation of components of the Polycomb Repressor Complex 2 rescued proliferation inhibition caused by the CDK4/6 inhibitor palbociclib, but not to inhibitors of S phase or mitosis. In addition to its core catalytic subunits, mutation of the PRC2.1 accessory protein MTF2, but not the PRC2.2 protein JARID2, rendered cells resistant to palbociclib treatment. We found that PRC2.1 (MTF2), but not PRC2.2 (JARID2), was critical for promoting H3K27me3 deposition at CpG islands genome-wide and in promoters. This included the CpG islands in the promoter of the CDK4/6 cyclins CCND1 and CCND2, and loss of MTF2 lead to upregulation of both CCND1 and CCND2. Our results demonstrate a role for PRC2.1, but not PRC2.2, in antagonizing G1 progression in a diversity of cell linages, including chronic myeloid leukemia (CML), breast cancer, and immortalized cell lines.